Evidence map›Paper›PMID 24569552›Full record

ReviewCurrent opinion in endocrinology, diabetes, and obesity2014

Type 2 diabetes and cardiovascular disease: what next?

Joshua J Joseph, Sherita Hill Golden

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in endocrinology, diabetes, and obesity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. The Place of Sulfonylureas in the Evolving Landscape of Combination Therapy.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
    Review
  11. Article
  12. Article
  13. Urinary sodium-to-potassium ratio and serum asymmetric dimethylarginine levels in patients with type 2 diabetes.Hypertension research : official journal of the Japanese Society of Hypertension · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Aldosterone, Renin, and Diabetes Mellitus in African Americans: The Jackson Heart Study.The Journal of clinical endocrinology and metabolism · 2016
    Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Joshua J JosephaDivision of Endocrinology, Diabetes and Metabolism, Johns Hopkins University School of Medicine bDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Sherita Hill Golden
Johns Hopkins Medicine · US

Funding

JHU-UMD Diabetes Research CenterP30DK079637 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI AHIMA, REXFORD S. · 2013 to 2017
$9.7M
Clinical Research&Epidemiology in Diabetes&EndocrinologyT32DK062707 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI TODD T BROWN, Wendy Lynet Bennett · 2002 to 2026
$7.3M
NIDDK NIH HHS P30 DK079637NIDDK NIH HHS T32 DK062707
6 · The paper itself

Abstract

purpose of reviewCardiovascular disease (CVD) is the leading cause of mortality in type 2 diabetes mellitus (T2DM), and modifying cardiovascular risk through lifestyle intervention and pharmacologic therapy is paramount. This review focuses on recent advances in treatment of classical (traditional) cardiovascular risk factors and highlights the impact of novel risk factors, including sleep disorders, socioeconomic status and chronic psychological stress on CVD in T2DM. RECENT

findingsObesity is a substantial cardiovascular risk factor, and recently, large trials of lifestyle and surgical (e.g. gastric bypass) interventions impact on CVD in overweight and obese patients have been reported. Lifestyle intervention including low calorie diet and exercise reduced individual cardiovascular risk factors but did not decrease the rate of long-term cardiovascular events. Bariatric surgery was beneficial in reducing cardiovascular risk factors and long-term cardiovascular events. Sleep insufficiency, poor sleep quality and obstructive sleep apnoea lead to higher CVD and further research is needed to characterize the benefit of treating sleep disorders on long-term cardiovascular events in T2DM. Lastly, socioeconomic status and chronic psychological stress independently have a major impact on increasing CVD in T2DM, and public health policies to reduce this burden will be important to address over the coming decade. SUMMARY: CVD in T2DM is multifactorial and requires a multifaceted approach in reducing known cardiovascular risks at the individual patient level through lifestyle, pharmacotherapy and surgical interventions and at the societal level through public health policies that support reduction in classical and novel cardiovascular risk factors.

Indexed as

Anticholesteremic AgentsAspirinBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic AngiopathiesDrug Therapy, CombinationExerciseFemaleGlycated HemoglobinHumansHypoglycemic AgentsMaleObesityRisk FactorsRisk Reduction BehaviorAnticholesteremic AgentsAspirinBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsSimvastatin

Identifiers

PMID24569552
PMCPMC5704916
OpenAlexW2110845218

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.